Early combination therapy for type 2 diabetes. Time for new decisions
https://doi.org/10.21518/2079-701X-2019-12-115-121
Abstract
The morbidity of diabetes mellitus is steadily increasing worldwide. Most of the patients with type 2 diabetes, many of whom already have complications when diagnosed. Strategy and tactics of treatment of patients with DM2 today are one of the priorities of modern medicine.
About the Author
L. V. Kondratyeva
Federal State Budgetary Educational Institution of Additional Professional Education Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Kondratyeva Larisa Vasilyevna - Cand. of Sci. (Med.), Associate Professor.
125993, Moscow, Barrikadnaya St., 2/1, b. 1; Tel.: +7(916) 544-55-90
References
1. IDF Diabetes Atlas, 8th edition. Brussels: International Diabetes Federation; 2017. Available from: https://www.idf.org/e-library/epidemiologyresearch/diabetesatlas/134-idf-diabetes-atlas8th-edition.html.
2. Carls G., Huynh J., Tuttle E. et al. Achivment of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014. Diabetes ther. 2017;8(4):863-873. doi:10.1007/s13300-017-0280-5.
3. Hu F.B., Stampfer MJ., Haffiier S.M., Solomon C.G., Willett W.C., Manson J.E. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care. 2002 Jul;25(7):1129-1134.
4. Reaven G.M. The role of insulin resistance and hyperinsulinemia in coronary heart disease. Metabolism. 1992;41(5), Suppl. 1:16-19.
5. Hsueh W.A., Law R.E. Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am. J. Med. 1998;105(1A):4S-14.
6. Morrish NJ., Wang S.L., Stevens L.K., Fuller J.H. et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44(2):14-21.
7. Budoff MJ. Not all diabetics are created equal (in cardiovascular risk). Eur. Heart J. 2008;29(18):2193-2194.
8. Haffner S.M., Lehto S., Ronnemaa T. Mortality from coronary artery disease in subject with type 2 diabetes and nondiabetic subjects with and without myocardial infarction. The New England Journal of Medicine. 1998;339:229-34. https://doi.org/10.1056/NEJM199807233390404.
9. Dedov I.I., Shestakova M.V., Aleksandrov A.A. et al. Algorithms for specialized medical care in diabetes mellitus (5th edition). Sakharnyi Diabet. Prilozhenie. 2011;3. (In Russ.)
10. Dedov I.I., Shestakova M.V., Maiorov A. Algorithms for specialized medical care in diabetes mellitus. 8th edition. Sakharnyi Diabet. 2017;8:1-112. doi: 1014341/DM20171S8. (In Russ.)
11. International Diabetes Federation (IDF) Diabetes Atlas, 8th Edition. Brussels, Belgium: International Diabetes Federation, 2017.
12. Dedov I.I., Shestakova M.V., Maiorov A.Yu. Algorithms for specialized medical care in diabetes mellitus. 2019; 9th edition: 20. (In Russ.)
13. Khunti K., Wolden M.L., Thorsted B.L. et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411-3417.
14. Inzucchi S.E., Bergenstral R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-149. doi: 10.2337/dc14-2441.16.
15. Turner R.C. et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). JAMA. 1999;281(21):2005-12.
16. UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
17. Liu Y, Hong T. Combination therapy of dipepti-dyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. Diabetes Obes Metab, 2014;16(2):111-117. https://doi.org/10.1111/dom.12128. Epub 2013 Jun 3.
18. Wu D., Li L., Liu C. Efficacy and safety of dipep-tidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab. 2014;16(1):30-37. https://doi.org/10.1111/dom.12174. Epub 2013 Jul 16.
19. Bianchi C., Daniele G., Dardano A., Miccoli R., Del Prato S. Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2. Diabetes. Drugs. 2017; 77(3):247-264.
20. Cho Y.M., Kieffer TJ. New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitizer. Diabetologia. 2011;54(2):219-222.
21. Davies MJ., DAlessio D.A., Fradkin J., Kerman W.N. et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018 Dec;41(12):2669-2701. https://doi.org/10.2337/dci18-0033.
22. Capuano A., Giugliano D., Sportiello L. et al. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy - focus on alogliptin. Drug Des. Devel. Ther. 2013;7:989-1001. http://dx.doi.org/10.2147/DDDT.S37647.
23. Nauck M.A, Ellis G.C, Fleck P.R, Wilson C.A, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009;63:46-55.
24. Bosi E., Ellis G.C, Wilson C.A, Fleck P.R. Alogliptin as a third oral antidiabeticdrug in patients with type 2 diabetes and inadequate glycaemic control onmetformin and pioglita-zone: a 52-week, randomized, double-blind, activecontrolled, parallel-group study. Diabetes Obes Metab. 2011;13:1088-1096.
25. Rosenstock J., Rendell M.S., Gross J.L., Fleck P.R., Wilson C.A., Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1c) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009;11:1145-1152.
26. Zannad F., Cannon C.P., Cushman W.C. et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067-2076.
27. Russian Society of Endocrinologists. Administration of aloglip-tin benzoate (Vipidia®) for the treatment of patients with type 2 diabetes in real clinical practice in the Russian Federation. Announcements of interim analyses. Sakharnyi Diabet. 2018;21(5). (In Russ.)
28. Inzucchi S.E., Bergenstal R.M., Buse J.B. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379.
29. Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-2443.
30. Phung OJ., Scholle J.M., Talwar M., Coleman C.I. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010;303(14):1410-1418.
31. Del Prato S., Camisasca R., Wilson C., Fleck P Durability of the efficacy and safety of aloglip-tin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab. 2014;16:1239-1246.
32. Bianchi C. et al. Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. Drugs. 2017; 77:247-264. doi: 10.1007/s40265-017-0694-4.
Review
For citations:
Kondratyeva LV. Early combination therapy for type 2 diabetes. Time for new decisions. Meditsinskiy sovet = Medical Council. 2019;(12):115-121. (In Russ.) https://doi.org/10.21518/2079-701X-2019-12-115-121
Views:
679
Email this article 